ProCE Banner Series

Advances in BTK Inhibitor Therapy for B-Cell Lymphomas: Expert Discussion and Resources to Elevate Patient Care

Join us at this live webinar for expert discussions and takeaways on the role of BTK inhibitors for patients with B-cell lymphomas.

  AAPA
  | ANCC
Who Should Attend

This program is intended for hematology/oncology nurses, physician associates, and other healthcare professionals caring for patients with B-cell lymphomas.

All Events

Advances in BTK Inhibitor Therapy for B-Cell Lymphomas: Expert Discussion and Resources to Elevate Patient Care

Upcoming Events

November

16

2024

8:10 AM - 9:10 AM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Emily Patterson, AGACNP-BC

Massachusetts General Hospital
Lymphoma Clinic
Boston, Massachusetts

Topics

Lymphomas

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve the knowledge, confidence, and competence of hematology/oncology nurses to understand and optimally apply available clinical data to nursing practice on BTK inhibitors in the treatment of B-cell lymphomas in order to improve patient care. 

Target Audience
This program is intended for hematology/oncology nurses, physician associates, and other healthcare professionals caring for patients with B-cell lymphomas.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Explain differences in BTK inhibitors to patients with B-cell lymphomas, including current and emerging indications, safety, and treatment resistance
  • Develop strategies to maintain adherence and persistence to prescribed BTK inhibitor regimens for patients with B-cell lymphomas
  • Manage and mitigate adverse events associated with BTK inhibitor therapy in patients with B-cell lymphomas
  • Counsel patients with B-cell malignancies on ongoing clinical trial opportunities with BTK inhibitor therapy to ensure inclusive enrollment opportunities and equitable care

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour, including 1.0 hour of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC.

Supported by an educational grant from BeiGene.